News Future uncertain for Innate and BMS' troubled lirilumab Doubts over future of cancer immunotherapy
News NICE okays CDF funding for BMS' Opdivo in head and neck canc... Cancer Drugs Fund will reimburse Opdivo for 2 years
News BMS' Opdivo approved in head and neck cancer BMS hopes survival data will give advantage over rival.
News NICE rejects head and neck cancer drug once again NICE rejects German Merck's Erbitux, unsure of effectiveness.
R&D The long-delayed promise of the microbiome, with Sam Possemi... Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
